11:21 AM EDT, 03/20/2024 (MT Newswires) -- Labcorp (LH) said Wednesday it has introduced at test to identify the presence or absence of a biomarker in the bloodstream to assist with the diagnosis and monitoring of patients with Alzheimer's disease.

The new test was developed to identify patients with the phosphorylated tau 217 biomarker, which has been used by physicians to monitor Alzheimer's patients on anti-amyloid therapy.

Labcorp previously introduced three other blood-based tests used to diagnose and treat Alzheimer's disease, including a test indicating its likely severity by measuring the level of neurodegeneration in patients.

Price: 210.01, Change: -0.96, Percent Change: -0.46